Hepatitis C drug patent

India rejects Gilead\’s Hepatitis C drug patent request

(Reuters) – India\’s patent office has rejected an application from U.S.-based Gilead Sciences Inc for its hepatitis C drug Sovaldi, paving the way for local drugmakers to launch cheaper generic versions of the $1,000-a-pill medicine.

India rejects Gilead\’s Hepatitis C drug patent request Read More »

India rejects Gilead\’s Hepatitis C drug patent request

Novedades

As Gilead is the sole producer of sofosbuvir (no generic versions have been launched in any country), governments, MSF and other treatment providers are dependent on the willingness of the company to make this urgently-needed drug available and accessible.

India rejects Gilead\’s Hepatitis C drug patent request Read More »